Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

Jordan S. Orange; Elham M. Hossny; Catherine R. Weiler; Mark Ballow; Melvin Berger; Francisco A. Bonilla; Rebecca Buckley; Javier Chinen; Yehia El-Gamal; Bruce D. Mazer; Robert P. Nelson; Dhavalkumar D. Patel; Elizabeth Secord; Ricardo U. Sorensen; Richard L. Wasserman; Charlotte Cunningham-Rundles

doi:10.1016/j.jaci.2006.01.015

Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

Jordan S. Orange
, Elham M. Hossny
, Catherine R. Weiler
, Mark Ballow
, Melvin Berger
, Francisco A. Bonilla
, Rebecca Buckley
, Javier Chinen
, Yehia El-Gamal
, Bruce D. Mazer
, Robert P. Nelson
, Dhavalkumar D. Patel
, Elizabeth Secord
, Ricardo U. Sorensen
, Richard L. Wasserman
, Charlotte Cunningham-Rundles

Research output: Contribution to journal › Article › peer-review

625 Scopus citations

Abstract

Human immunoglobulin prepared for intravenous administration (IGIV) has a number of important uses in the treatment of disease. Some of these are in diseases for which acceptable treatment alternatives do not exist. In this review we have evaluated the evidence underlying a wide variety of IGIV uses and make specific recommendations on the basis of these data. Given the potential risks and inherent scarcity of IGIV, careful consideration of the indications for and administration of IGIV is warranted.

Original language	English
Pages (from-to)	S525-S553
Journal	Journal of Allergy and Clinical Immunology
Volume	117
Issue number	4 SUPPL.
DOIs	https://doi.org/10.1016/j.jaci.2006.01.015
State	Published - Apr 2006

Keywords

Adverse events
Autoimmunity
IGIV
Immunoglobulin
Immunomodulation
Intravenous immunoglobulin
Primary immunodeficiency
Transfusion

Access to Document

10.1016/j.jaci.2006.01.015

Cite this

Orange, J. S., Hossny, E. M., Weiler, C. R., Ballow, M., Berger, M., Bonilla, F. A., Buckley, R., Chinen, J., El-Gamal, Y., Mazer, B. D., Nelson, R. P., Patel, D. D., Secord, E., Sorensen, R. U., Wasserman, R. L., & Cunningham-Rundles, C. (2006). Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Journal of Allergy and Clinical Immunology, 117(4 SUPPL.), S525-S553. https://doi.org/10.1016/j.jaci.2006.01.015

@article{b3f8ed7a528b4d3fa1c7082ad53c3591,

title = "Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology",

abstract = "Human immunoglobulin prepared for intravenous administration (IGIV) has a number of important uses in the treatment of disease. Some of these are in diseases for which acceptable treatment alternatives do not exist. In this review we have evaluated the evidence underlying a wide variety of IGIV uses and make specific recommendations on the basis of these data. Given the potential risks and inherent scarcity of IGIV, careful consideration of the indications for and administration of IGIV is warranted.",

keywords = "Adverse events, Autoimmunity, IGIV, Immunoglobulin, Immunomodulation, Intravenous immunoglobulin, Primary immunodeficiency, Transfusion",

author = "Orange, \{Jordan S.\} and Hossny, \{Elham M.\} and Weiler, \{Catherine R.\} and Mark Ballow and Melvin Berger and Bonilla, \{Francisco A.\} and Rebecca Buckley and Javier Chinen and Yehia El-Gamal and Mazer, \{Bruce D.\} and Nelson, \{Robert P.\} and Patel, \{Dhavalkumar D.\} and Elizabeth Secord and Sorensen, \{Ricardo U.\} and Wasserman, \{Richard L.\} and Charlotte Cunningham-Rundles",

year = "2006",

month = apr,

doi = "10.1016/j.jaci.2006.01.015",

language = "English",

volume = "117",

pages = "S525--S553",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "4 SUPPL.",

}

Orange, JS, Hossny, EM, Weiler, CR, Ballow, M, Berger, M, Bonilla, FA, Buckley, R, Chinen, J, El-Gamal, Y, Mazer, BD, Nelson, RP, Patel, DD, Secord, E, Sorensen, RU, Wasserman, RL & Cunningham-Rundles, C 2006, 'Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology', Journal of Allergy and Clinical Immunology, vol. 117, no. 4 SUPPL., pp. S525-S553. https://doi.org/10.1016/j.jaci.2006.01.015

Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. / Orange, Jordan S.; Hossny, Elham M.; Weiler, Catherine R. et al.
In: Journal of Allergy and Clinical Immunology, Vol. 117, No. 4 SUPPL., 04.2006, p. S525-S553.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Use of intravenous immunoglobulin in human disease

T2 - A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

AU - Orange, Jordan S.

AU - Hossny, Elham M.

AU - Weiler, Catherine R.

AU - Ballow, Mark

AU - Berger, Melvin

AU - Bonilla, Francisco A.

AU - Buckley, Rebecca

AU - Chinen, Javier

AU - El-Gamal, Yehia

AU - Mazer, Bruce D.

AU - Nelson, Robert P.

AU - Patel, Dhavalkumar D.

AU - Secord, Elizabeth

AU - Sorensen, Ricardo U.

AU - Wasserman, Richard L.

AU - Cunningham-Rundles, Charlotte

PY - 2006/4

Y1 - 2006/4

N2 - Human immunoglobulin prepared for intravenous administration (IGIV) has a number of important uses in the treatment of disease. Some of these are in diseases for which acceptable treatment alternatives do not exist. In this review we have evaluated the evidence underlying a wide variety of IGIV uses and make specific recommendations on the basis of these data. Given the potential risks and inherent scarcity of IGIV, careful consideration of the indications for and administration of IGIV is warranted.

AB - Human immunoglobulin prepared for intravenous administration (IGIV) has a number of important uses in the treatment of disease. Some of these are in diseases for which acceptable treatment alternatives do not exist. In this review we have evaluated the evidence underlying a wide variety of IGIV uses and make specific recommendations on the basis of these data. Given the potential risks and inherent scarcity of IGIV, careful consideration of the indications for and administration of IGIV is warranted.

KW - Adverse events

KW - Autoimmunity

KW - IGIV

KW - Immunoglobulin

KW - Immunomodulation

KW - Intravenous immunoglobulin

KW - Primary immunodeficiency

KW - Transfusion

UR - https://www.scopus.com/pages/publications/33645341439

U2 - 10.1016/j.jaci.2006.01.015

DO - 10.1016/j.jaci.2006.01.015

M3 - Article

C2 - 16580469

AN - SCOPUS:33645341439

SN - 0091-6749

VL - 117

SP - S525-S553

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 4 SUPPL.

ER -

Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

Abstract

Keywords

Access to Document

Fingerprint

Cite this